FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385496712> ?p ?o ?g. }

• W4385496712 abstract "To date, real-world evidence on persistence to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) or onabotulinumtoxinA have excluded eptinezumab. This retrospective cohort study was performed to compare treatment persistency among patients with migraine on anti-CGRP mAbs (erenumab, fremanezumab, galcanezumab, or eptinezumab) or onabotulinumtoxinA.This retrospective study used IQVIA PharmMetrics data. Adult patients with migraine treated with an anti-CGRP mAb or onabotulinumtoxinA who had 12 months of continuous insurance enrollment before starting treatment were included. A most recent treatment episode analysis was used in which the most recent episode was defined as the latest treatment period with the same drug (anti-CGRP mAb or onabotulinumtoxinA) without a ≥ 15-day gap in medication supply on/after June 25, 2020, to December 31, 2021. Patients were indexed at the start of their most recent episode. Patients were considered non-persistent and discontinued the therapy associated with their most recent episode if there was ≥ 15-day gap in medication supply. A Cox proportional-hazards model estimated the discontinuation hazard between treatments. The gap periods and cohort definition were varied in sensitivity analyses.The study included 66,576 patients (median age 46 years, 88.6% female). More eptinezumab-treated patients had chronic migraine (727/1074), ≥ 3 previous acute (323/1074) or preventive (333/1074) therapies, and more prior treatment episodes (3) than other treatment groups. Based on a 15-day treatment gap, patients on subcutaneous anti-CGRP mAbs had a 32% (95% CI: 1.19, 1.49; erenumab), 42% (95% CI: 1.27, 1.61; galcanezumab), and 58% (95% CI: 1.42, 1.80; fremanezumab) higher discontinuation hazard than those receiving eptinezumab, with this relationship attenuated, but still statistically significant based on 30-day and 60-day treatment gaps. There was no significant difference in the discontinuation hazard between eptinezumab and onabotulinumtoxinA. Based on a 15-day treatment gap among patients who newly initiated therapy, the discontinuation hazard of subcutaneous anti-CGRP mAbs remained significantly higher compared to eptinezumab and onabotulinumtoxinA.Patients treated with eptinezumab demonstrated persistency that was higher than subcutaneous anti-CGRP mAbs and similar to onabotulinumtoxinA." @default.
• W4385496712 created "2023-08-03" @default.
• W4385496712 creator A5008054238 @default.
• W4385496712 creator A5039355461 @default.
• W4385496712 creator A5049092477 @default.
• W4385496712 creator A5054026041 @default.
• W4385496712 creator A5054051543 @default.
• W4385496712 creator A5065860775 @default.
• W4385496712 creator A5073499736 @default.
• W4385496712 creator A5088567770 @default.
• W4385496712 date "2023-08-02" @default.
• W4385496712 modified "2023-10-16" @default.
• W4385496712 title "Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study" @default.
• W4385496712 cites W2005239637 @default.
• W4385496712 cites W2007410119 @default.
• W4385496712 cites W2139062201 @default.
• W4385496712 cites W2746714361 @default.
• W4385496712 cites W3157009111 @default.
• W4385496712 cites W3173551259 @default.
• W4385496712 cites W4230120862 @default.
• W4385496712 doi "https://doi.org/10.1186/s10194-023-01636-8" @default.
• W4385496712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37532991" @default.
• W4385496712 hasPublicationYear "2023" @default.
• W4385496712 type Work @default.
• W4385496712 citedByCount "0" @default.
• W4385496712 crossrefType "journal-article" @default.
• W4385496712 hasAuthorship W4385496712A5008054238 @default.
• W4385496712 hasAuthorship W4385496712A5039355461 @default.
• W4385496712 hasAuthorship W4385496712A5049092477 @default.
• W4385496712 hasAuthorship W4385496712A5054026041 @default.
• W4385496712 hasAuthorship W4385496712A5054051543 @default.
• W4385496712 hasAuthorship W4385496712A5065860775 @default.
• W4385496712 hasAuthorship W4385496712A5073499736 @default.
• W4385496712 hasAuthorship W4385496712A5088567770 @default.
• W4385496712 hasBestOaLocation W43854967121 @default.
• W4385496712 hasConcept C118303440 @default.
• W4385496712 hasConcept C126322002 @default.
• W4385496712 hasConcept C163170386 @default.
• W4385496712 hasConcept C167135981 @default.
• W4385496712 hasConcept C170493617 @default.
• W4385496712 hasConcept C187212893 @default.
• W4385496712 hasConcept C207103383 @default.
• W4385496712 hasConcept C2778541695 @default.
• W4385496712 hasConcept C2778715236 @default.
• W4385496712 hasConcept C2910587157 @default.
• W4385496712 hasConcept C44249647 @default.
• W4385496712 hasConcept C71924100 @default.
• W4385496712 hasConcept C72563966 @default.
• W4385496712 hasConceptScore W4385496712C118303440 @default.
• W4385496712 hasConceptScore W4385496712C126322002 @default.
• W4385496712 hasConceptScore W4385496712C163170386 @default.
• W4385496712 hasConceptScore W4385496712C167135981 @default.
• W4385496712 hasConceptScore W4385496712C170493617 @default.
• W4385496712 hasConceptScore W4385496712C187212893 @default.
• W4385496712 hasConceptScore W4385496712C207103383 @default.
• W4385496712 hasConceptScore W4385496712C2778541695 @default.
• W4385496712 hasConceptScore W4385496712C2778715236 @default.
• W4385496712 hasConceptScore W4385496712C2910587157 @default.
• W4385496712 hasConceptScore W4385496712C44249647 @default.
• W4385496712 hasConceptScore W4385496712C71924100 @default.
• W4385496712 hasConceptScore W4385496712C72563966 @default.
• W4385496712 hasIssue "1" @default.
• W4385496712 hasLocation W43854967121 @default.
• W4385496712 hasLocation W43854967122 @default.
• W4385496712 hasOpenAccess W4385496712 @default.
• W4385496712 hasPrimaryLocation W43854967121 @default.
• W4385496712 hasRelatedWork W2883290297 @default.
• W4385496712 hasRelatedWork W2948901586 @default.
• W4385496712 hasRelatedWork W3038802552 @default.
• W4385496712 hasRelatedWork W3162640449 @default.
• W4385496712 hasRelatedWork W3199883053 @default.
• W4385496712 hasRelatedWork W3207819762 @default.
• W4385496712 hasRelatedWork W3207849898 @default.
• W4385496712 hasRelatedWork W4206992385 @default.
• W4385496712 hasRelatedWork W4210511822 @default.
• W4385496712 hasRelatedWork W4367721089 @default.
• W4385496712 hasVolume "24" @default.
• W4385496712 isParatext "false" @default.
• W4385496712 isRetracted "false" @default.
• W4385496712 workType "article" @default.